Physician profile
Melanie E Costa
NPI 1801976733
$2,977.86
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $294 · 2021: $270 · 2022: $570 · 2023: $560 · 2024: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.48 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,096.45 | 2019-2023 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $465.29 | 2019-2024 | |
| Dermavant Sciences, INC. | $393.49 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $220.10 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $200.12 | 2019 | |
| Galderma Laboratories, L.P. | $184.36 | 2019-2021 | |
| Genzyme Corporation | $128.67 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $127.91 | 2019-2021 | |
| Pfizer INC. | $45.08 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $33.56 | 2020-2022 | |
| Amgen INC. | $31.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.37 | 2019 | |
| Encore Dermatology INC. | $14.03 | 2019 | |
| Mayne Pharma Commercial LLC | $4.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.